Showing results (101-110 of 617) with videos related to

Sort By:
Pageof 62
Onkologie|January 31, 2012
Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disordersAndreas Hochhaus, Andreas Reiter, Thomas Ernst, et al.
ACG Case Reports Journal|November 19, 2019
Colonic Wall Thickening as the First Indicator of Relapse of Acute Lymphoblastic LeukemiaKelly E Hathorn, Marlise R Luskin, Michael Travis Caton, et al.
Genes, Chromosomes & Cancer|July 12, 2008
Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemiaJennifer L Poitras, Paola Dal Cin, Jon C Aster, et al.
Clinical and Translational Science|August 20, 2020
Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic LeukemiaJoseph Chen, May Haughey, Erik Vandendries, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 8, 2014
Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysisDaniel J DeAngelo, Lei Chen, Annie Guerin, et al.
Blood Reviews|April 27, 2020
Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathologyKerem Ozturk, Zuzan Cayci, Jason Gotlib, et al.
Journal of the American Academy of Dermatology|February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER studyFrank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.
American Journal of Hematology|November 14, 2008
A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromesJason Gotlib, Philip Lavori, Sylvia Quesada, et al.
Expert Review of Hematology|October 3, 2013
Practical management of patients with myelofibrosis receiving ruxolitinibClaire Harrison, Ruben Mesa, David Ross, et al.
Blood Advances|September 2, 2021
Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trialsAndrew Hantel, Marlise R Luskin, Jacqueline S Garcia, et al.
Pageof 62